Free Trial

Phathom Pharmaceuticals (PHAT) News Today

→ It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad)
Free PHAT Stock Alerts
$10.60
+0.92 (+9.50%)
(As of 06/7/2024 08:52 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 9 at 4:58 PM | marketbeat.com
Catalys Pacific LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Catalys Pacific LLC purchased a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 721,962 shares of the company's
June 9 at 5:12 AM | americanbankingnews.com
Financial Survey: Phathom Pharmaceuticals (NASDAQ:PHAT) vs. Xilio Therapeutics (NASDAQ:XLO)
June 9 at 2:20 AM | americanbankingnews.com
Needham & Company LLC Reiterates Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)
June 7 at 9:11 AM | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns "Buy" Rating from Needham & Company LLC
Needham & Company LLC restated a "buy" rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday.
June 7 at 6:17 AM | investorplace.com
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
June 6, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6%
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6%
June 5, 2024 | americanbankingnews.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 8.1%
June 3, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 8.1% Higher
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 8.1%
June 2, 2024 | americanbankingnews.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.9%
June 2, 2024 | americanbankingnews.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Reaffirmed by Needham & Company LLC
May 31, 2024 | marketbeat.com
Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a report on Friday.
May 30, 2024 | marketbeat.com
Decheng Capital LLC Purchases Shares of 850,000 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Decheng Capital LLC purchased a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 850,000 shares of the company's
May 28, 2024 | globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 25, 2024 | markets.businessinsider.com
Strong Market Uptake of Phathom Pharmaceuticals’ V oquezna Signals Promising Growth
May 23, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)
May 17, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday.
May 15, 2024 | finance.yahoo.com
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 14, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 8.7%
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 8.7% Higher
May 13, 2024 | finance.yahoo.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
May 10, 2024 | investorplace.com
The 3 Best Healthcare Stocks to Buy in May 2024
May 9, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Rating Reiterated by Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday.
May 9, 2024 | globenewswire.com
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Promising Pipeline Developments
May 7, 2024 | markets.businessinsider.com
Buy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial Outlook
May 7, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.9%
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 5.9%
May 7, 2024 | markets.businessinsider.com
Optimistic Outlook: Buy Recommendation for Stoke Therapeutics Amidst Strategic Progress and Anticipated Clinical Milestones
May 6, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 11.8%
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 11.8%
May 3, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market Trajectory
May 3, 2024 | msn.com
Stifel Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy Recommendation
May 3, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Analysts at Stifel Nicolaus
Stifel Nicolaus began coverage on Phathom Pharmaceuticals in a research note on Friday. They set a "buy" rating and a $24.00 target price for the company.
May 2, 2024 | msn.com
Peloton stock sinks to record low as CEO steps down
May 2, 2024 | msn.com
Miami sports mogul receives $10 billion offer for his assets, here's why he rejected the deal
April 29, 2024 | finance.yahoo.com
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
April 26, 2024 | markets.businessinsider.com
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oquezna
April 23, 2024 | markets.businessinsider.com
Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)
April 19, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)
April 19, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oquezna
April 19, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.7%
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.7%
April 19, 2024 | finance.yahoo.com
12 Most Shorted Stocks in 2024
April 15, 2024 | marketbeat.com
Vanguard Group Inc. Has $19.94 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Vanguard Group Inc. increased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 10.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,922,662 shares of the company's stock
April 12, 2024 | investing.com
Phathom Pharmaceuticals CFO sells over $38k in company stock
April 11, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.2% After Insider Selling
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.2% After Insider Selling
April 11, 2024 | insidertrades.com
Molly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock
April 10, 2024 | markets.businessinsider.com
Buy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising Pipeline
April 9, 2024 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
April 7, 2024 | msn.com
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst
April 6, 2024 | markets.businessinsider.com
Optimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data Fluctuations
April 5, 2024 | finance.yahoo.com
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
April 4, 2024 | marketbeat.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 5.5%
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5%
April 3, 2024 | finance.yahoo.com
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Get Phathom Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.

It's time to ween off Chinese lithium! (Ad)

As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely

Learn how this American company is leading the lithium-ion revolution

PHAT Media Mentions By Week

PHAT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PHAT
News Sentiment
▼
0.31

0.76
▲
Average
Medical
News Sentiment

PHAT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PHAT Articles
This Week
▼
9

3
▲
PHAT Articles
Average Week

Get Phathom Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:PHAT) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
RSVP: Charles Payne’s Cash Flow Workshop
Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...
Unstoppable Prosperity | Sponsored